Screener
Amylyx Pharmaceuticals, Inc. AMLX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s total equity?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total equity of $239.17M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total equity increased by 42.5% year-over-year, from $167.88M to $239.17M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Amylyx Pharmaceuticals, Inc.'s total equity has grown at a 35.5% compound annual growth rate (CAGR), from -$66.73M to $305.26M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude